✦ LIBER ✦

Phase II trial of temsirolimus in patients with metastatic breast cancer

✍ Scribed by Gini F. Fleming, Cynthia X. Ma, Dezheng Huo, Husain Sattar, Maria Tretiakova, L. Lin, Olwen M. Hahn, F. O. Olopade, R. Nanda, Philip C. Hoffman, M. J. Naughton, Timothy Pluard, Suzanne D. Conzen, Matthew J. Ellis

Book ID: 118796611
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 235 KB
Volume: 136
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1910-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of temsirolimus in seco

A phase II trial of temsirolimus in second-line metastatic urothelial cancer

✍ H. Gerullis, C. Eimer, T. H. Ecke, E. Georgas, C. Freitas, S. Kastenholz, C. Arn 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 222 KB

C147 TEMSIROLIMUS IN SECOND-LINE METASTA

C147 TEMSIROLIMUS IN SECOND-LINE METASTATIC UROTHELIAL CANCER- A PHASE II TRIAL

✍ Gerullis, H.; Eimer, C.; Georgas, E.; Otto, T. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Phase II trial of piroxantrone in metast

Phase II trial of piroxantrone in metastatic breast cancer

✍ Peter M. Ravdin; Stephanie Green; James H. Doroshow; Silvana Martino 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 274 KB

A phase II trial of imatinib mesylate mo

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

✍ Shanu Modi; Andrew D. Seidman; Maura Dickler; Mark Moasser; Gabriella D’Andrea; 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 255 KB

A phase I trial of the IGF-1R antibody C

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

✍ Ma, Cynthia X.; Suman, Vera J.; Goetz, Matthew; Haluska, Paul; Moynihan, Timothy 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 301 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi